Gilead Earnings Surge As Hep C Drug Shatters Views
Gilead Sciences late Tuesday blew past Q1 revenue and earnings forecasts as sales of its new hepatitis C drug Sovaldi far exceeded expectations, but fellow big biotech Amgen missed expectations. Gilead (GILD) stock was up 2.5% after hours, after its Q1 report included sales of $2.27 billion for the expensive Sovaldi, which it started selling in December. Analyst sales estimates ranged from near ...
At Investor's Business Daily: http://news.investors.com/technology/042214-697968-gilead-q1-beats-as-hep-c-drug-exceeds-expectations.htm#ixzz3Z1Vcc3j4
Follow us: @IBDinvestors on Twitter | InvestorsBusinessDaily on Facebook
No comments:
Post a Comment